Genetic polymorphisms in the matrix metalloproteinase 12 gene (MMP12) and breast cancer risk and survival: the Shanghai Breast Cancer Study

Table 4 Association of MMP12 A-82G and A1082G polymorphism with survival in 1,125 breast cancer patients

MMP12 genotype	Events/subjects	5-year survival rate (%)	Crude HR (and 95% CI)	Adjusted HR^a (and 95% CI)
Overall survival
A-82G
AA	173/1059	84.4	1.0	1.0
AG/GG	10/55	81.4	1.14 (0.60–2.16)	1.06 (0.56–2.00)
AG	9/51	82.0
GG	1/4	75.0
A1082G (Asn357Ser)
AA	108/738	86.0	1.0	1.0
AG/GG	34/181	81.0	1.33 (0.90–1.95)	1.36 (0.92–2.00)
AG	32/157	79.4
GG	2/24	91.7
Presence of any minor genotypes^b
No	99/686	86.3	1.0	1.0
Yes	43/222	80.4	1.40 (0.98–2.00)	1.42 (0.99–2.04)
Disease-free survival
A-82G
AA	224/1059	78.8	1.0	1.0
AG/GG	10/55	81.7	0.87 (0.46–1.64)	0.80 (0.42–1.51)
AG	9/51	82.3
GG	1/4	75.0
A1082G (Asn357Ser)
AA	151/738	79.5	1.0	1.0
AG/GG	38/181	78.8	1.04 (0.73–1.49)	1.07 (0.74–1.52)
AG	35/157	77.5
GG	3/24	87.5
Presence of any minor genotypes^b
No	142/686	79.3	1.0	1.0
Yes	47/222	78.7	1.04 (0.75–1.45)	1.06 (0.76–1.47)

^aAdjusted for age, TNM stage, and ER/PR status. ^bAG/GG genotypes for A-82G and AG/GG genotype for A1082G polymorphisms. CI, confidence interval; ER, estrogen receptor; HR = hazard ratio; PR, progesterone receptor; TNM, tumor, node, metastasis.

ISSN: 1465-542X